Skip to main content
. 2020 Apr 1;19(6):3859–3870. doi: 10.3892/ol.2020.11502

Figure 5.

Figure 5.

Genetic alterations prior to treatment with osimertinib based on next-generation sequencing, targeting 59 genes from 21 patients with T790M-positive cases resistant to first- or second-generation EGFR-tyrosine kinase inhibitors. EGFR, epidermal growth factor receptor; PR, partial response; SD, stable disease; PD, progressive disease; VAF, variant allele frequency.